- Key Publications
The Cardiovascular Pathophysiology & Therapeutics Group reflects the combined interests of members of The Queen Elizabeth Hospital’s (TQEH) Cardiology and Clinical Pharmacology groups. This research collaboration has existed for over the past 20 years at TQEH.
We are mainly interested in developing a better understanding of the “new” cardiovascular epidemics of the 21st century, including atrial fibrillation, systolic hypertension, aortic valve disease, stress “Tako-Tsubo” cardiomyopathy and metabolic heart disease. We recognise that these conditions are responsible for impaired quality of life, as well as increased mortality rates. Therefore, we consider the development of effective treatment modalities as a major priority.
Emeritus Professor John D Horowitz
Position: Lead Researcher
Dr Yuliy Chirkov
Position: Principal Medical Scientist
Professor Betty Sallustio
Position: Principal Medical Scientist
Phone: +61 8 8222 6510
UoA: Betty Sallustio
Dr T Ha Nguyen
Position: Postdoctoral Researcher
Phone: +61 8 8 8222 7632
Dr Saifei Liu
Position: Postdoctoral Researcher
Dr Cher-Rin Chong
Position: Postdoctoral Research Fellow
Phone: +61 8 8133 4062
UoA: Cher-Rin Chong
Position: Laboratory Manager
Dr Chuks Ajaero
Position: Scientific Officer
Dr Gao Jing Ong
Student Alumni (since 2016)
|Name||Degree||Year Awarded||Thesis title||Supervisors|
|Sven Surikow||PhD, The University of Adelaide||2019||Nitrosative stress and the pathogenesis of Takotsubo Syndrome: Insights from a novel female rat model||Horowitz JD, Nguyen H, Chirkov Y|
|Hasan Imam||PhD, The University of Adelaide||2018||Post-receptor signalling mechanisms and platelet responsiveness to ADP receptor antagonists||Horowitz JD, Chirkov Y|
|Chuks Ajaero||PhD, The University of Adelaide||2018||Interactions between Cardiac Resynchronisation Therapy and Amelioration of Peripheral Vascular Dysfunction: Impact upon Outcomes||Horowitz JD, Arstall M, Chan A, McGavigan A|
|Dongqing (Kelly) Chan||First Class Honours, The University of Adelaide||2018||Early detection of chemotherapy-induced cardiomyopathy||Horowitz JD, Liu S|
|Vivek Nooney||PhD, University of South Australia||2017||Determinants of clinical responses to platelet ADP receptor antagonists||Roberts MS, Horowitz JD, Chirkov Y|
|Cher-Rin Chong||PhD, The University of Adelaide||2017||A pharmacological approach towards myocardial protection: new perspectives in acute and chronic cardiac disease||Horowitz JD, Sallustio B|
|Zaipul MD Dom||PhD, The University of Adelaide||2017||Mycophenolic acid pharmacokinetics and clinical outcomes in renal transplantation: Effect of ABCC2 haplotype analysis and distribution into lymphocytes and kidney||Sallustio BC, Somogyi AA, Coller JK|
|Matthew Chapman||MResearch, The University of Adelaide||2016||Pathogenesis of valvular and aortic degenerative changes in association with bicuspid aortic valve||Horowitz JD, Nguyen TH|
|G Mahadavan||PhD, The University of Adelaide||2016||The pathophysiology and potential therapeutics of diastolic heart failure||Frenneaux MP, Horowitz JD|
|N Hurst||PhD, The University of Adelaide||2016||The effect of the nitric oxide and prostacyclin pathways on platelet aggregation||Horowitz JD, Chirkov Y, McRae S|
- Coronary artery spasm
- Preventing heart damage during cancer chemotherapy
- Maximising protective effects of BNP in patients with heart failure
- Variability of anti-aggregatory effects of P2Y12 receptor antagonists: therapeutic adjustments
- Improving outcomes after takotsubo (broken heart) syndrome
Please also refer to page 97 of the BHI Research Report 2019.
Kikuchi R, Nakamura K, MacLauchlan S, Ngo DT, Shimizu I, Fuster JJ, Katanasaka Y, Yoshida S, Qiu Y, Yamaguchi TP, Matsushita T, Murohara T, Gokce N, Bates DO, Hamburg NM, Walsh K. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat Med; 2014. 20(12): 1464-71.
Ngo DT, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, Bates DO, LaValley MP, Hamburg NM, Vita JA, Hess DT, Walsh K, Gokce N. Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation; 2014. 130(13): 1072-80.
Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, Liesa M, Shirihai OS, Rimer J, Schaffer JE, Wilson S C, Edward J M. Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload. J Mol Cell Cardiol; 2015. 79: 275-83.
Siddiqi N, Neil C, Bruce M, MacLennan G, Cotton S, Papadopoulou S, Feelisch M, Bunce N, Lim PO, Hildick-Smith D, Horowitz J, Madhani M, Boon N, Dawson D, Kaski JC, Frenneaux M; NIAMI investigators. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur Heart J; 2014. 35(19): 1255-62.
Sverdlov AL, Ngo DT, Chan WP, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD. Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. Eur Heart J; 2012. 33(19): 2419-25.
Nitrosative stress and diagnosis/treatment of stress cardiomyopathy.
JD Horowitz/Y Chirkov. University of Adelaide
Funding since 2010
|Chief Investigators||Granting Body||Project Title||Total Grant Amount||Funding Period|
|Chong CR||National Health & Medical Research Council (NHMRC) Peter Doherty Biomedical ECR Fellowship (#1162356)||Novel strategy to prevent cardiovascular complications in diabetes: the role of poly(ADP-ribose) polymerase-1 inhibition||$327,193||2019 - 2022|
|Sallustio B, Evdokiou A, Horowitz JD||National Health & Medical Research Council (NHMRC) Project Grant (#1145776)||Prevention of heart damage during Anthracycline cancer chemotherapy||$327,214||2018 - 2020|
|Ritchie R, Horowitz J, Kemp-Harper B, Du XJ, Chirkov Y||National Health & Medical Research Council (NHMRC) Project Grant (#1120895)||Therapeutic approaches to circumvent NO• resistance in the Type 2 diabetic heart and vasculature||$576,743||2017 - 2019|
|Frenneaux M, Horowitz JD||Medical Research Council, UK||Therapeutic aspects of nitrite supplementation||$3,500,000||2014 - 2019|
|Sallustio BC, Evdokiou A, Horowitz JD||The Hospital Research Foundation/The University of Adelaide||Equipment: Vivid Iq Premium, Rodent Echocardiography System||$77,600||2018|
|Stewart S, Horowitz JD, Carrington M, Scuffham P, Wong C, Newton P, Rischbieth A||National Health & Medical Research Council (NHMRC)||Which Heart failure Intervention is most Cost effective in reducing Hospital care (WHICH? II) Trial: A multicentre, randomised trial of standard versus intensified management of metropolitan and regional-dwelling patients with heart failure||$1,817,825||2013 - 2018|
|Ngo D||The Hospital Research Foundation (THRF) Mid Career Fellowship||Modulation of the anti-angiogenic VEGF-A165b in adipose tissue: novel approach to combat obesity||$360,000||2015 - 2017|
|Sverdlov A||National Health & Medical Research Council (NHMRC) CJ Martin Biomedical Fellowship (#1037603)||Lipotoxicity, mitochondrial dysfunction|
and the pathogenesis of heart failure
|$364,884||2012 - 2017|
|Sverdlov A||The University of Adelaide Start Up Grant||Are mitochondrial reactive oxygen species key mediators of metabolic syndrome induced heart disease||$10,000||2017|
|Frenneaux M, Feelisch M, Horowitz JD et al.||Medical Research Council, UK||Effect of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and therapeutic potential||£2.3 million ||2011 - 2016
|Dawson D, Neil CJ, Horowitz JD, Frenneaux MP||Tenovus Scotland Grant, UK||G13/10 Stress induced Heart Disease||£9,990||2013 - 2014
|Sallustio B, Horowitz JD, Kennedy JA, Frenneaux MP||National Heart Foundation||Utility of (+)- and (-) perhexiline as model compounds for the development of new myocardial metabolic agents||$130,000||2012 - 2013
|Sorich M, Horowitz JD||National Heart Foundation||Assessing of the value of the confirmatory studies required for the widespread uptake of personalised cardiovascular medicine||$64,602||2012|
|Horowitz JD, Selvanayagam J, Semsarian C, Atherton J||National Heart Foundation ||Multiparametric Cardiovascular Magnetic Resonance Assessment of Hypertrophic cardiomyopathy||$130,000||2010 - 2011
Please refer to page 26 of the BHI Research Report 2019.
|Baker Heart and Diabetes Institute||Melbourne||Australia|
|Department of Epidemiology and Preventative Medicine, Monash University||Melbourne||Australia|
|Department of Pharmacology, Monash University||Melbourne||Australia|
|Australian Catholic University||Melbourne||Australia|
|The University of Newcastle||Newcastle||Australia|
|Cardiology Department, University of Aberdeen||Aberdeen||Scotland, UK|
|University of East Anglia||Norwich||England, UK|
|University of Oxford||Oxford||England, UK|
|Department of Biochemistry, University of Hannover||Hannover||Germany|
|Department of Medicine, Boston University||Boston||USA|
|Department of Medicine, University of Pittsburgh||Pittsburgh||USA|